Abstract
BackgroundLimited evidence is available on the association of insulin-like growth factors (IGFs) and risk of heart failure in population-based samples. We investigated whether serum IGFs concentrations can predict mortality from heart failure.MethodsWe conducted a nested case-control study of 39,242 subjects aged 40–79 years who participated in the JACC study, a large Japanese prospective cohort study; participants provided serum samples and were followed up for 9 years. In heart failure cases and age-, sex-, community-, and year of blood withdrawal-matched controls, we measured serum concentrations of IGF-I, IGF-II, and IGF binding protein 3 (IGFBP3) and transforming growth factor (TGF-β1).ResultsDuring the follow-up, there were 88 heart failure deaths (44 men and 44 women). Each increment of 1 standard deviation [SD] of IGF-II (120.0 ng/mL in women and 143.7 ng/mL in men) was associated with a 47% reduced risk of mortality from heart failure; multivariable odds ratio was 0.53 (95% confidence interval [CI], 0.30–0.94, P-trend = 0.03). The multivariable odds ratio in the highest quartile of IGFBP3 serum concentrations (≥3.29 µg/mL in women and ≥3.31 µg/mL in men) compared with the lowest (<2.11 µg/mL in women and <2.56 µg/mL in men) was 0.24 (95% CI, 0.05–1.11; P-trend = 0.12). No association was found between serum concentrations of IGF-I or TGF-β1 and risk of heart failure.ConclusionsHigher serum concentrations of IGF-II were associated with lower mortality from heart failure, which might suggest a possible role of IGF-II in the occurrence or prognosis of heart failure.
Highlights
The failing heart results from a complex syndrome that based on the mechanical failure of the myocardium to provide adequate systematic perfusion, and involves activation of various neurohumoral, immunologic, and biological mechanisms, as a result of or in accompany to myocardial injury.[1]
Insulin-like growth factors I and II (IGF-I and -II) are singlechain polypeptides, respectively composed of 70 and 67 amino acids, which are involved in proliferation, migration, contractility regulation, and apoptosis inhibition of vascular smooth muscle cells, like that of the myocardium.[2,3]
Within participants of the Japan Collaborative Cohort study (JACC), we investigated the associations of serum concentrations of insulin-like growth factors (IGFs)-I, IGF-II, IGF binding protein 3 (IGFBP3), and transforming growth factor β1 (TGF-β1) with mortality from heart failure in a nested case-control study
Summary
The failing heart results from a complex syndrome that based on the mechanical failure of the myocardium to provide adequate systematic perfusion, and involves activation of various neurohumoral, immunologic, and biological mechanisms, as a result of or in accompany to myocardial injury.[1] Provoking factors for this injury to the vascular smooth muscle cells include hypertension, diabetes, ischemic heart disease, congenital heart disease, cardiomyopathies, myocarditis, and other conditions.[1]. There has been growing evidence for the associations of IGFs concentrations with different provoking factors of heart failure; inverse associations of higher IGFs levels and positive associations of lower IGFs levels with risks of atherosclerosis,[5] hypertension,[6] diabetes,[7] congenital heart disease,[8] and cardiovascular disease,[9,10] especially ischemic heart disease.[11,12] based on their promotive role in myocyte growth, high. We investigated whether serum IGFs concentrations can predict mortality from heart failure
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
